Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; 500 mg, 1000 mg) |
| Drug Class | Iron chelators |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias.
Latest News
Summary
- This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
- Iron Chelation Therapy (ICT) in Thalassemia Patients: Deferiprone showed high compliance rates (87.2-92.2%) compared to desferioxamine (48.84-85.1%) and deferasirox (90-100%). Increased compliance correlated with lower serum ferritin levels, reduced risks of liver and cardiac diseases, endocrinologic morbidity, and improved health-related quality of life (HRQoL).
- Friedreich Ataxia (FA): Deferiprone showed no significant improvement across severity scales (the International Cooperative Ataxia Rating Scale (ICARS), the Friedreich Ataxia Rating Scale (FARS), the Assessment And Rating of Ataxia (SARA), the Activities of Daily Living (ADL)), with most studies reporting patient deterioration regardless of intervention or inconclusive results.
- Sickle Cell Disease (SCD) and Thalassemia: Adherence rates for deferiprone ranged from 69% to 95% compared to deferoxamine (71% to 93%), with trials reporting no difference in quality of life (QoL) outcomes.
- Friedreich Ataxia (FA): Serious adverse events (SAEs) reported with deferiprone include atrial fibrillation, craniocerebral injury, and ventricular tachycardia.
- SCD, Thalassemia, and Superficial Siderosis: SAEs associated with deferiprone include a 1-2% risk of agranulocytosis in SCD and thalassemia, with superficial siderosis patients experiencing a 21.7% incidence of anemia, 8.7% incidence of neutropenia, and 5.8% incidence of agranulocytosis.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ferriprox (deferiprone) Prescribing Information. | 2021 | Chiesi USA, Inc., Cary, NC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review | 2024 | Health and Quality of Life Outcomes |
| Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia | 2023 | The Cochrane Database of Systematic Reviews |
| Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review | 2022 | Therapeutic Advances in Rare Disease |
| Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review | 2021 | Cerebellum |